Reappraisal of immunologic mechanisms of hypomethylating agents in treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia

被引：0
|
作者：
Hong, Junshik
Min, Suji
Park, Jihyun
Fielder, Carly M.
Hu, Qianni
Yoon, Sung-Soo
Kim, Tae Kon
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-3269
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3269
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes
    Wang, Hong
    Li, Yan
    Lv, Na
    Li, Yonghui
    Wang, Lili
    Yu, Li
    ANNALS OF HEMATOLOGY, 2018, 97 (11) : 2025 - 2038
  • [22] A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
    Gemici, Aliihsan
    Ozkalemkas, Fahir
    Dogu, Mehmet Hilmi
    Tekinalp, Atakan
    Alacacioglu, Inci
    Guney, Tekin
    Ince, Idris
    Geduk, Ayfer
    Cagliyan, Gulsum Akgun
    Maral, Senem
    Serin, Istemi
    Gunduz, Eren
    Karakus, Volkan
    Bekoz, Huseyin Saffet
    Eren, Rafet
    Pinar, Ibrahim Ethem
    Gunes, Ahmet Kursad
    Sargin, Fatma Deniz
    Sevindik, Omur Gokmen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (08): : E686 - E692
  • [23] Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies
    Stomper, Julia
    Rotondo, John Charles
    Greve, Gabriele
    Luebbert, Michael
    LEUKEMIA, 2021, 35 (07) : 1873 - 1889
  • [24] Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies
    Julia Stomper
    John Charles Rotondo
    Gabriele Greve
    Michael Lübbert
    Leukemia, 2021, 35 : 1873 - 1889
  • [25] Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant
    Motabi, Ibraheem H.
    Ghobadi, Armin
    Liu, Jingxia
    Schroeder, Mark
    Abboud, Camille N.
    Cashen, Amanda F.
    Stockier-Goldstein, Keith E.
    Uy, Geoffrey L.
    Vij, Ravi
    Westervelt, Peter
    DiPersio, John F.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (07) : 1324 - 1329
  • [26] Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
    P Tan
    A Wei
    S Mithraprabhu
    N Cummings
    H B Liu
    M Perugini
    K Reed
    S Avery
    S Patil
    P Walker
    P Mollee
    A Grigg
    R D'Andrea
    A Dear
    A Spencer
    Blood Cancer Journal, 2014, 4 : e170 - e170
  • [27] Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
    Tan, P.
    Wei, A.
    Mithraprabhu, S.
    Cummings, N.
    Liu, H. B.
    Perugini, M.
    Reed, K.
    Avery, S.
    Patil, S.
    Walker, P.
    Mollee, P.
    Grigg, A.
    D'Andrea, R.
    Dear, A.
    Spencer, A.
    BLOOD CANCER JOURNAL, 2014, 4 : e170 - e170
  • [28] Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia
    Wei, Andrew
    Tan, Peter
    LEUKEMIA & LYMPHOMA, 2013, 54 (04) : 675 - 676
  • [29] Outcome of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome According to Health Insurance Status
    Al-Ameri, Ali
    Anand, Ankit
    Abdelfatah, Mohamed
    Kanaan, Zeyad
    Hammonds, Tracy
    Haller, Nairmeen
    Cherry, Mohamad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (06): : 509 - 513
  • [30] Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches
    Deschler, Barbara
    de Witte, Theo
    Mertelsmann, Roland
    Luebbert, Michael
    HAEMATOLOGICA, 2006, 91 (11) : 1513 - 1522
12345